Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesJaguar Animal Health Inc

Jaguar Animal Health Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.5432 USD -0.34 ( 38.56%)
Last update at 2026-11-03T20:54:00Z
VOLUME
3134974
Market Cap
1.16M

Momentum Score

…

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.51
Low
0.69
High
52 Week Price Range
0.20
Low
85.40
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Jaguar Animal Health Inc is a U.S.-based animal health company focused on developing and commercializing therapeutics and products for veterinary use. Its long-term growth may be driven by gaining regulatory approvals for pipeline products, expanding commercial distribution, and licensing or partnerships, which could support revenue diversification and scale.

Principal risks include regulatory and clinical development failure, competition from larger animal-health companies, and limited operating scale and liquidity that could constrain commercialization and require additional financing.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.88
Dividend Yield
-
Revenue TTM
27.82M
Revenue Per Share
82.71
Gross Profit TTM
22.89M
Debt / Equity
-2.52
ROE
-548.83%
Net Debt
42.64M
ROCE
2313.60%
Diluted EPS TTM
98.20

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -54.00M -39.25M -41.90M -48.40M -52.60M
Minority interest 0.56M 0.76M 1.11M 0.94M 0.01M
Net income -53.43M -38.49M -41.30M -47.45M -60.25M
Selling general administrative 21.85M 16.33M 16.59M 17.87M 17.10M
Selling and marketing expenses 4.17M 7.69M 6.46M 8.84M 8.89M
Gross profit 7.74M 9.73M 7.72M 9.94M 2.00M
Reconciled depreciation 2.20M 2.36M 2.40M 2.29M 1.81M
Ebit -53.93M -39.02M -33.92M -34.41M -39.07M
Ebitda -51.73M -36.66M -32.76M -31.17M -39.66M
Depreciation and amortization 2.20M 2.36M 1.16M 3.24M -0.59M
Operating income -45.11M -30.83M -34.29M -34.41M -39.07M
Other operating expenses 56.62M 42.52M 44.05M 46.37M 43.41M
Interest expense 0.07M 0.23M 6.38M 12.72M 8.42M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Net interest income -0.07M -0.23M -8.77M -12.72M -10.05M
Income tax expense -0.42M -0.76M -0.60M -0.94M 7.65M
Total revenue 11.51M 11.69M 9.76M 11.96M 4.33M
Total operating expenses 52.84M 40.56M 42.02M 44.35M 41.08M
Cost of revenue 3.77M 1.96M 2.04M 2.02M 2.33M
Total other income expense net -8.89M -8.42M -7.61M -13.98M -13.53M
Net income from continuing ops -54.00M -39.25M -40.82M -48.40M -52.60M
Net income applicable to common shares - - - - -52.59M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 38.32M 53.42M 50.76M 47.45M 53.27M
Intangible assets 16.02M 18.48M 20.12M 22.44M 22.65M
Other current assets 9.08M 12.20M 10.12M 7.36M 4.34M
Total liab 57.01M 46.93M 45.87M 48.81M 41.41M
Total stockholder equity -17.29M 7.29M 4.96M -0.66M 11.61M
Other current liab 4.17M 1.80M 3.80M 8.16M 0.00M
Common stock 0.00M - 0.01M - 0.01M
Capital stock 2.49M 0.00M - 0.00M 0.01M
Retained earnings -399.92M -346.48M -308.25M -266.95M -219.49M
Other assets - - 0.00M - 0.45M
Cash 0.97M 8.00M 6.47M 5.47M 17.05M
Total current liabilities 40.65M 19.70M 13.99M 30.34M 15.47M
Current deferred revenue 0.17M 0.17M - - 7.12M
Net debt 42.64M 28.52M 30.62M 29.37M 12.31M
Short term debt 27.63M 12.34M 5.21M 16.37M 3.42M
Short long term debt 27.44M 12.04M - 15.88M 3.18M
Short long term debt total 43.61M 36.53M 37.09M 34.84M 29.36M
Other stockholder equity 380.97M 354.23M 313.85M 266.97M 231.10M
Property plant equipment - - - - 1.73M
Total current assets 20.34M 32.20M 27.96M 22.32M 28.43M
Net tangible assets - - - - -11.04M
Net receivables 1.70M 1.65M 2.18M 2.47M 2.14M
Long term debt 15.08M 23.50M - 17.74M 25.02M
Inventory 8.60M 10.35M 9.19M 7.02M 4.90M
Accounts payable 8.69M 5.29M 4.97M 5.81M 4.93M
Accumulated other comprehensive income -0.83M -0.47M -0.65M -0.68M -
Non currrent assets other 0.49M 1.35M 1.01M 0.99M 0.45M
Non current assets total 17.98M 21.23M 22.80M 25.13M 24.83M
Capital lease obligations 1.08M 0.98M - 1.21M 1.16M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.23M -0.36M -1.68M -0.01M
Change to liabilities - - - - 0.16M
Total cashflows from investing activities 0.15M -0.23M 1.23M - -0.01M
Net borrowings 13.35M -0.10M -0.10M - 8.11M
Total cash from financing activities -44.33M 31.20M 34.23M 23.18M 43.94M
Change to operating activities - - - - 1.40M
Net income -15.37M -39.03M -41.87M -49.08M -52.60M
Change in cash -38.35M 1.53M 1.00M -11.58M 8.96M
Begin period cash flow 46.19M 6.47M 5.47M 17.05M 8.09M
End period cash flow 7.83M 8.00M 6.47M 5.47M 17.05M
Total cash from operating activities 5.80M -29.38M -33.24M -33.10M -34.97M
Issuance of capital stock 10.98M 31.91M 24.13M 20.46M 33.58M
Depreciation 0.00M 2.36M 2.39M 2.29M 1.81M
Other cashflows from investing activities 0.17M -0.21M - - -
Change to inventory 0.90M -1.16M -2.17M -2.12M -2.12M
Change to account receivables -0.43M 0.53M 0.30M -0.17M 2.82M
Sale purchase of stock -31.07M - - - -
Other cashflows from financing activities 5.79M -0.61M 2.23M 2.82M 12.28M
Change to netincome - - - - 8.38M
Capital expenditures 0.03M 0.23M 0.00M 1.68M 0.01M
Change in working capital 12.89M -3.01M -11.10M -4.43M 2.27M
Stock based compensation -0.81M 1.64M 2.11M 3.32M 3.97M
Other non cash items 9.09M 8.66M 15.23M 14.79M 5.19M
Free cash flow 5.77M -29.61M -33.24M -34.78M -34.98M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
JAGX
Jaguar Animal Health Inc		 -0.34
38.56%		 0.54 - 200.00 0.04 0.24 0.58 -0.63
NVO
Novo Nordisk A/S		 -0.24
0.61%		 40.20 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -21.28
3.85%		 531.87 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 12.10
1.26%		 973.36 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Jaguar Animal Health Inc

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

200 Pine Street, San Francisco, CA, United States, 94104

415 371 8300

https://jaguar.health

47

Name Title Year Born
Ms. Lisa A. Conte Founder, CEO, Pres & Director 1959
Mr. Jonathan S. Wolin CPA, J.D., M.B.A. Chief of Staff, Chief Compliance Officer & Gen. Counsel 1962
Mr. Ian H. Wendt M.B.A. Chief Commercial Officer 1968
Dr. Steven R. King Ph.D. Chief of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Sec. 1958
Ms. Carol R. Lizak Chief Financial Officer 1964
Dr. Pravin R. Chaturvedi Ph.D. Chief Scientific Officer & Chair of Scientific Advisory Board 1963
Mr. Peter Hodge Sr. Director of Investor Relations, Bus. Devel. & Special Events NA
Dr. Karen J. Brunke Ph.D. Exec. VP of Corp. & Bus. Devel. 1952
Mr. David Sesin Chief Manufacturing Officer NA
Dr. Michael K. Guy D.V.M., M.S., Ph.D. VP of Preclinical & Nonclinical Studies NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

VNP
CAD 32.54
+24.44%
HUT
CAD 88.32
+14.81%
KEEL
CAD 3.05
+14.66%
MTY
CAD 36.63
+13.58%
CNL
CAD 15.98
+11.90%
MOON
CAD 4.72
-12.34%
EU
CAD 0.96
-8.57%
URE
CAD 1.02
-8.48%
AP-UN
CAD 3.71
-8.17%
HG
CAD 3.77
-8.05%

Equity Sectors*

  • Basic Materials

    -1.14%

  • Communication Services

    +0.65%

  • Consumer Cyclical

    +0.09%

  • Consumer Defensive

    -0.57%

  • Energy

    -0.15%

  • Financial Services

    +0.08%

  • Healthcare

    +2.18%

  • Industrials

    +2.04%

  • Real Estate

    -0.25%

  • Technology

    +1.02%

  • Utilities

    +0.66%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…